Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil prices extend losses as supply disruption fears ease
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Intellia Therapeutics (NTLA) Reports Q1 Loss of $0.49/Share
May 2, 2019 7:43 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.49), versus ($0.51) reported last year. Revenue for the quarter came in at $10.43 million, versus $7.47 million reported last year.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
... More